FDA: Novartis recall may also affect painkillers

By MATTHEW PERRONE , AP Health Writer

(AP) -- The Food and Drug Administration is warning patients about a potential mix-up between powerful prescription pain drugs and common over-the-counter medications like Excedrin and Gas-X made at a Novartis manufacturing plant.

The problem stems from major manufacturing problems at a Lincoln, Neb., facility which triggered a sweeping recall of the company's over-the-counter drugs on Sunday. The company has received complaints of broken and chipped pills, and inconsistent bottle packaging that could cause pills to be mixed up. Consumers should not use the products and can contact the company for a refund.

FDA officials warned Monday that some of Novartis' over-the-counter pills may have accidentally been packaged with powerful prescription painkillers made at the same facility. The opioid drugs are sold by Endo Pharmaceuticals as Percocet, Endocet, Opana and Zydone.

Endo Pharmaceuticals Holdings Inc., of Chadds Ford, Pa., said it is not aware of any confirmed product mix-ups or injuries.

FDA officials say they are not recalling the painkillers because they are essential medications for many patients and the risks of stray pills are low.

"The likelihood of finding a wrong tablet in an opiate pain medication dispensed to patients is low and patients should not be unduly alarmed," FDA's Dr. Edward Cox told reporters.

Cox said regulators are also concerned about a shortage of Endo's painkillers in coming weeks due to the shutdown of the Nebraska facility. Switzerland-based Novartis voluntarily halted production at the plant last month.

"FDA is working with Endo and Novartis to minimize the degree of impact. The degree of shortage will depend upon how quickly safeguards can be put in place to prevent this manufacturing issue from happening in the future," the FDA said in a statement on its website.

FDA inspectors cited Novartis' plant for dozens of quality control problems last summer, in a report posted to the agency's website. Company officials repeatedly failed to properly follow up on consumer complaints received since 2009. FDA inspectors concluded that none of the 223 complaints received by the plant last year were properly reviewed, according to the report.

Novartis announced Sunday it would recall certain bottles of headache medicine Excedrin and caffeine caplets NoDoz with expiration dates of Dec. 20, 2014. The company is also recalling some packages of pain medicine Bufferin and stomach medicine Gas-X with expiration dates of Dec. 20, 2013, or earlier.

Customers can also call the company at 1-888-477-2403 Monday to Friday, 9 a.m. to 8 p.m. EST.

The FDA and Endo Pharmaceuticals recommend patients examine their prescriptions to make sure all the tablets are similar in shape, color, size and marking. If one or more of the tablets look different, patients should return the medicine to their pharmacist.

Patients can call Endo Pharmaceuticals' call center at 1-800-462-3636.

3 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Swiss pharma giant Novartis recalls drugs in US

Jan 08, 2012

Swiss pharmaceutical firm Novartis said Sunday it was recalling four different products sold over the counter in the United States over reports of a malfunction at one of its plants.

Senator warns FDA on danger of newest painkillers

Jan 08, 2012

Following fatal shootings in two New York pharmacy robberies, a U.S. senator is warning that a new batch of "super painkillers" now under review could force repeats of recent violent robberies that left six people dead.

FDA orders lower doses in prescription painkillers

Jan 13, 2011

(AP) -- Federal health regulators are limiting a key ingredient found in Vicodin, Percocet and other prescription painkillers that have been linked to thousands of cases of liver damage each year.

FDA cracks down on untested cold medicines

Mar 02, 2011

(AP) -- The Food and Drug Administration says it will remove roughly 500 unapproved cold and allergy medications from the market as part of an ongoing campaign cracking down on ineffective prescription medications.

Recommended for you

FDA proposes accelerated medical device approval plan

17 hours ago

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical ...

Targeting drugs to reduce side effects

23 hours ago

(Medical Xpress)—Consider ice cream – the base of which is frozen cream. Ingredients are then added to make different flavours. All these flavours are distinctly different but are created from the same foundation.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Jesse_EngAmer
4 / 5 (1) Jan 09, 2012
Praise should be given to the FDA for handling this properly. However, shouldn't the FDA of acted more preventatively? They knew of the complaints as early as last year. Why was no action taken earlier?